.png){kind=icon}
.png){kind=icon}
Return
Comparative Metabolic Safety of Efavirenz-, Dolutegravir-, and Bictegravir-based antiretroviral regimens in HIV-Infected Adults: Evidence for Weight-Dependent Lipid Deterioration
.png){kind=icon}
OA
AI
J
C
R
Z
Y
B
Y
Y
Y
J
S
Z
S
DOI：10.1016/j.jiph.2026.103293.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The second-generation integrase strand transfer inhibitors (INSTIs) are gradually replacing efavirenz (EFV) in antiretroviral therapy due to their superior efficacy and tolerability. However, there are still concerns about their long-term metabolic safety, particularly weight gain and dyslipidemia. In real-world settings, comparative evidence on the longitudinal metabolic effects of EFV, dolutegravir (DTG), and bictegravir (BIC) in the Asian population is still limited. This study evaluated the metabolic trajectories of these regimens and explored the mediating role of weight gain in hypertriglyceridemia(HTG).
Keywords:
HIV
integrase strand transfer inhibitors
antiretroviral regimens
weight gain
hypertriglyceridemia
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4
Papers:
570
Citations:
7.0K
Organization
Cited Papers